Cabozantinib plus atezolizumab in advanced hepatocellular carcinoma and the role of adjuvant antiviral therapy
- PMID: 35798015
- DOI: 10.1016/S1470-2045(22)00383-7
Cabozantinib plus atezolizumab in advanced hepatocellular carcinoma and the role of adjuvant antiviral therapy
Conflict of interest statement
FJ reports speaker's fees from Gilead Sciences, MSD, and Ascletis; and consulting or advisory board fees from Gilead and MSD. MHN reports grants from Gilead, Pfizer, Enanta, Vir, Glycotest, National Cancer Institute, B K Kee Foundation, Exact Sciences, and Helio Health; and consulting or advisory board fees from Intercept, Gilead, Exact Sciences, Laboratory of Advanced Medicine, Bayer, Eisai, GSK, and Novartis.
Comment on
-
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.Lancet Oncol. 2022 Aug;23(8):995-1008. doi: 10.1016/S1470-2045(22)00326-6. Epub 2022 Jul 4. Lancet Oncol. 2022. PMID: 35798016 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical